Key result
An editorial discusses a retrospective analysis of the ORBIT-AF registries evaluating residual stroke, systemic embolism, and TIA risk in atrial fibrillation patients on oral anticoagulation.
Why the study?
What is the magnitude of residual risk for stroke, systemic embolism, and TIA in atrial fibrillation patients treated with oral anticoagulation?
What is the magnitude of residual risk for stroke, systemic embolism, and TIA in atrial fibrillation patients treated with oral anticoagulation?
Answers are grounded in this paper and cite their sources.
Highlights the importance of understanding residual stroke and systemic embolism risk in atrial fibrillation patients receiving oral anticoagulation.
In this issue of Heart Rhythm O2, Carlisle, et al. performed a retrospective analysis of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I and II) trials to define the magnitude of residual risk for stroke and systemic embolism (SSE) and transient ischemic attack (TIA) in atrial fibrillation (AF) patients treated with oral anticoagulation (OAC). 1. Orbit I gathered data on real- world treatment of AF including rate and rhythm control, stroke prevention, and clinical outcomes among AF patients in community practice settings 2.
No takes yet. Share an insight, caveat, or question.
Taya V. Glotzer (2022) conducted an editorial in Atrial fibrillation. Oral anticoagulation (OAC) was evaluated on Residual risk for stroke and systemic embolism (SSE) and transient ischemic attack (TIA). An editorial discusses a retrospective analysis of the ORBIT-AF registries evaluating residual stroke, systemic embolism, and TIA risk in atrial fibrillation patients on oral anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: